If we were able to read the tiny, microscopic signs of our immune systems, we could catch and treat diseases like ovarian or pancreatic cancer before they become deadly. An early screening tool like that could save millions of lives a year — and Microsoft is working to make it a reality.

The tech giant announced Thursday that it is partnering with Seattle biotech company Adaptive Biotechnologies on a years-long project to build a universal blood test that can screen for dozens or even hundreds of diseases at a time, all by decoding the information in your immune system.

As part of the deal, Microsoft is investing an undisclosed sum in Adaptive and is offering the company cloud computing and machine learning services.